Image Credit: VisCardia
Portland-based Viscardia received FDA’s “Breakthrough Technology” designation for its VisONE® device, which delivers “Asymptomatic Diaphragmatic Stimulation” (ADS) therapy to improve cardiac function.
The idea is that by electrically stimulating the diaphragm in an asymptomatic manner, transient intrathoracic pressures gated to cardiac activity are applied against the cardiac walls, improving both cardiac filling and output.
VisCardia’s website: viscardia.com